跳至主要内容
临床试验/JPRN-UMIN000001262
JPRN-UMIN000001262已完成4 期

Post-marketing clinical study of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in vernal keratoconjunctivitis - Post-marketing clinical study of TALYMUS ophthalmic suspension 0.1% (tacrolimus) in vernal keratoconjunctivitis

Senju Pharmaceutical Co., Ltd.0 个研究点目标入组 50 人开始时间: 2008年9月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Subjects are ineligible to participate in this study, if they: 1. have a known hypersensitivity to tacrolimus hydrate or to any component of this drug 2. Are suffering from infectious eye disease 3. Are pregnant or may possibly be pregnant 4. Have used ocular tacrolimus hydrate(including clinical trials) 5. Need to take tacrolymus capsules, granules and/or injection(Prograf) 6. Need to wear contact lenses during treatment period 7. Have participated in any other clinical trials within 3 months prior to enrollment, or will be enrolled in any other clinical trials during the study period 8. Were judged an inadequate subject to enrollment by a medical doctor

研究者

相似试验